This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundIndividuals diagnosed with type 2 diabetes mellitus (T2DM) commonly exhibit elevated lipid levels and an increased body mass index (BMI). The impact of BMI on the efficacy of statins in reducing lipid levels among diabetic patients remains uncertain.
Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce. Individuals with diabetes had a 1.5-fold fold higher mean expenditure that those without diabetes. individuals aged ≥ 18 years.
Last month, the 2025 American Diabetes Association (ADA) guidelines were introduced, providing updates for diagnosing and managing diabetes and prediabetes. This ensures patients have contingency plans to maintain effective diabetes management during periods of unavailability.
We used conditional logistical regression models to estimate odds ratios and 95% CIs.RESULTS:There were 237 667 index admissions with AIS and diabetes during the study period. These results, if confirmed in other studies, emphasize the importance of avoiding hypoglycemic events in patients with diabetes.
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”
Non-smoker, doesn’t have diabetes and is on no medications. I'm Interested 1 Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. Here is a typical patient I might see in my clinical practice. 40 year old male with a family history of heart disease. LDL cholesterol = 4 mmol/l ( 155 mg/dl).
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”
Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.
Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. As social determinants of health are rarely included in risk models, we validated and recalibrated the WATCH-DM score in a diverse patient-group using their social deprivation index (SDI).Methods:We
Methods A total of 10 366 patients with chronic HF from 34 Dutch outpatient HF clinics were analysed regarding diuretic use and diuretic dose. Advanced symptoms, diabetes mellitus and worse renal function were significantly associated with a higher diuretic dose regardless of left ventricular ejection fraction.
When compared with placebo, glucagon-like peptide-1 receptor agonists such as once-weekly semaglutide (semaglutide OW T2D) improve cardiovascular outcomes in people with type 2 diabetes (T2D), whereas dipeptidyl peptidase-4 inhibitors (DPP-4is) do not. However, no head-to-head trials of these 2 incretin-based drug classes have been conducted.
Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. per 100 person years, p=0.012). per 100 person years, p=0.012). to 7.51, p=0.006).
The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.
Methods From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. In this study, we explore the use of WCD and evaluate arrhythmic events through comprehensive monitoring.
Reasons for not prescibing or discontinuing were: CKD 6, severe aortic stenosis 5, asthma 3, symptomatic bradycardia 5, hypotension 3, type1 diabetes 2, syncope 1, Raynauds 1, patient choice 8 and 6 patients died before all appropriate medications could be initiated. In 10 cases no clinical reason could be identified.It
Methods We used the Swedish Registry of Cardiopulmonary Resuscitation, merged with the Inpatient Registry and Outpatient Registry to identify patients with OHCA from 2010 to 2020 and to collect all their comorbidities as well as discharge diagnoses (among those admitted to hospital). had type 2 diabetes, compared with 19.6% of the men.
BackgroundAnnual heart transplant (HT) volumes have increased, as have post‐HT outpatient care needs. days), and comorbidity burden was high: 42% had hypertension, 38% had diabetes, and 31% had ≥2 comorbidities. Journal of the American Heart Association, Ahead of Print. Length of stay was 3.1 days (interquartile range, 1.6–5.9
Validated cut-points are provided to rule in or rule out acute heart failure in the emergency department and to diagnose de novo heart failure in the outpatient setting. diabetes, hypertension, coronary artery disease), underlying the development of cardiac dysfunction and further increased risk.
0.96]) decreased for low-income adults, while diabetes screening (RR 1.01 [0.95-1.08]) 1.08]) increased and diabetes focused visits and insulin use remained stable. However, routine outpatient visits and cardiovascular risk factor screening did not return back to pre-pandemic levels, while risk factor treatment remained stable.
METHODS:The J-HOP study enrolled outpatients with ≥1 cardiovascular risk factor between 2005 and 2012, with follow-up until March 2015 and extended follow-up from December 2017 to May 2018. Findings were similar in the subgroup of high-risk patients (those with diabetes or stroke history).CONCLUSIONS:These
Ensuring a follow-up neurology appointment within two weeks is vital to managing stroke risk factors like hypertension, diabetes, and atrial fibrillation. The clinic aims to support patients, manage stroke risk factors, and ensure a seamless transition to primary or outpatient neurology care.
His presentation raised concern for etiology such as vasculitis or multiple sclerosis and prompted a genetic workup, which was obtained on outpatient follow‐up. He had a documented history of transient‐ischemic attack and was noted to have undergone progressive cognitive decline.
Medical history: History of Ischemic Heart Disease History of Congestive Heart Failure Diabetes Mellitus requiring treatment with insulin Pre-operative serum creatinine >2 mg/dL He had this ECG recorded: What do you think? If the patient does not present with syncope, then outpatient management is probably OK, with referral to cardiology.
Higher troponin correlated with more history of heart failure, diabetes, and hypertension, as well as higher D-dimer, and nearly all inflammatory markers. Median age was 66.4 were over age 70, and 60% were men. CV disease was more prevalent in those with higher troponin.
Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. Inpatient and outpatient healthcare utilisation rates were highest in CKD and HF, and lowest in CKD and T2D. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.
We assessed the relationship of different ID definitions with cardiac structure and function, congestion, exercise capacity, and prognosis in HF outpatients. Conclusion In HF outpatients, TSAT <20% is more consistently associated with congestion by ultrasound and poorer functional capacity than other ID definitions, irrespective of LVEF.
Study Population includes all patients with an ischemic stroke inpatient admission in 2018 and were continuously enrolled with Medicare FFS for 1 year prior to and following their initial 2018 stroke admission. 1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content